From: Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
Clinical characteristics at diagnosis | ||||
---|---|---|---|---|
Total n = 72 | T ≤ 22 weeks n = 36 | T > 22 weeks n = 36 | p-value | |
Male sex | 74 | 70 | 78 | 0.42 |
Age, mean ± sd | 64 ± 12 | 66 ± 11 | 61 ± 13 | 0.10 |
Caucasian | 96 | 100 | 92 | 0.37 |
PR3 ANCA | 59 | 56 | 61 | 0.63 |
MPO ANCA | 42 | 44 | 39 | 0.63 |
ANCA-titre ≥4 times cut-off value | 85 | 94 | 75 | 0.03 |
Induction therapy cyclophosphamide and glucocorticoids | 75 | 78 | 72 | 0.49 |
Maintenance therapy azathioprine and glucocorticoids | 76 | 81 | 72 | 0.23 |
Organ involvementa | ||||
Pulmonary | 44 | 50 | 39 | 0.34 |
ENT | 43 | 31 | 56 | 0.03 |
Arthritis/arthralgia | 40 | 31 | 50 | 0.09 |
Neurologic | 31 | 25 | 36 | 0.31 |
Skin and soft tissue | 15 | 14 | 17 | 0.74 |
Type of AAV | ||||
GPA | 64 | 50 | 78 | 0.05 |
MPA | 32 | 44 | 19 | |
EGPA | 4 | 6 | 3 | |
Renal biopsy proven | 44 | 44 | 44 | 1.00 |
BVAS/WG at diagnosis, median (IQR) | 7 (3) | 7 (3) | 7 (3) | 0.71 |
Erythrocyturiab | 75 | 81 | 69 | 0.63 |
Renal insufficiencyc | 79 | 78 | 81 | 0.77 |
eGFR (ml/min), median (IQR)d | 34 (50) | 35 (50) | 30 (51) | 0.84 |
Proteinuriae | 81 | 75 | 87 | 0.21 |
CCI, median (IQR) | 0 (1) | 0 (1) | 0 (1) | 0.67 |
FFS, median (IQR) | 2 (2) | 2 (2) | 1 (2) | 0.12 |